Table 1.

Enterococcal strains used in this study

E. faecalis strainaDescriptionbDAP MIC (μg/ml)Reference/source
Laboratory strains
    V583 (CB807)Vancomycin-resistant (vanB) clinical isolate262
    DAP-A (CB2502)Day 12 isolate from V583 serial passage expt A256This study
    DAP-B (CB2503)Day 13 isolate from V583 serial passage expt B256This study
    DAP-C (CB2504)Day 14 isolate from V583 serial passage expt C512This study
    OG1RFHuman oral cavity isolate419
    OG1RF pAT28OG1RF plus shuttle vector pAT284This study
    KP101OG1RF plus pAT28 containing a 1,733-bp KpnI/XbaI fragment with V583 EF0631 and the putative EF0631 promoter region4This study
    KP102OG1RF plus pAT28 containing a 1,724-bp KpnI/XbaI fragment with DAP-A EF0631 and the putative EF0631 promoter region8This study
    KP103OG1RF plus pAT28 containing a 1,733-bp KpnI/XbaI fragment with DAP-C EF0631 and the putative EF0631 promoter region64This study
Clinical strains
    ACL-1781ESVSE, 12 March 2009 urine isolate; Indianac8LSId
    ESJH-1310ESVSE, 20 July 2008 coccyx wound isolate; Colorado8LSI
    MCA-1970ESVSE, 12 June 2009 body fluid isolate; Colorado32LSI
    NYU-529ESVSE, 19 January 2006 blood isolate; New York8LSI
    OHMC-239ESVSE, 27 February 2005 blood isolate; Washington8LSI
    SFOK-980ESVSE, 7 November 2007 blood isolate; Oklahoma8LSI
Sequential clinical strains
    Patient 1
        CMC-041EMVRE, 28 April 2004 blood isolate; New York456; LSI
        CMC-087EMVRE, 30 May 2004 blood isolate; New York>3256; LSI
        CMC-088EMVRE, 1 June 2004 blood isolate; New York>3256; LSI
    Patient 2
        UTHS-218EMVRE, 10 September 2004 urine isolate; Texas437; LSI
        UTHS-219EMVRE, 6 October 2004 blood isolate; Texas3237; LSI
  • a Where appropriate, Cubist strain identifiers (CB numbers) are shown.

  • b VSE, vancomycin-sensitive Enterococcus; VRE, vancomycin-resistant Enterococcus.

  • c Location of submitting laboratory.

  • d LSI = Daptomycin Reference Lab, Laboratory Specialists, Inc., Westlake, Ohio.